AVIR — Atea Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $407.92m
- $106.09m
Annual cashflow statement for Atea Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 121 | -116 | -136 | -168 | -158 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 39.6 | 41.3 | 34 | 39.9 | 15.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -248 | -46.6 | 16.2 | -7.48 | 16.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -87 | -121 | -85.4 | -135 | -132 |
| Capital Expenditures | -0.004 | -1.94 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -453 | 40.3 | 56.1 | 189 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.004 | -455 | 40.3 | 56.1 | 189 |
| Financing Cash Flow Items | — | — | — | — | -0.485 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 1.47 | 0.37 | 0.257 | 0.267 | -25.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -85.5 | -576 | -44.8 | -79.1 | 31 |